| Elizabeth J Boogusch, MD | |
|
17 Rockbrook Dr, Camden, ME 04843-1616 | |
| (207) 390-0647 | |
| (207) 470-1154 |
| Full Name | Elizabeth J Boogusch |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 30 Years |
| Location | 17 Rockbrook Dr, Camden, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801996772 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD14769 (Maine) | Primary |
| 207R00000X | Internal Medicine | MD14769 (Maine) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Penobscot Bay Medical Center | Rockport, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainehealth | 7517860588 | 2067 |
News Archive
Scientists at St George's, University of London and the University of Manchester have received an additional Seeding Drug Discovery award of £390,000 from the Wellcome Trust to explore a new class of experimental drugs that block the trigger of allergic reactions before symptoms show.
The first known patient cases using magnetic resonance-guided heat (laser interstitial thermal therapy) or cold (cryoablation) to treat prostate cancer recurrence after surgical removal of the prostate gland were presented by physicians at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa. Many of these patients have also failed salvage radiation treatment and are often presented with limited therapeutic options. MR-guided focal therapy offers a new treatment choice for patients because of the improved detection of early prostate cancer recurrences best seen with MR imaging.
Eli Lilly and Company and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.
Esteya, an electronic brachytherapy system, has received 510(k) clearance from the U.S. Food and Drug Administration, enabling medical centers in the United States to offer their patients with skin cancer a new treatment option.
› Verified 4 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Scientists at St George's, University of London and the University of Manchester have received an additional Seeding Drug Discovery award of £390,000 from the Wellcome Trust to explore a new class of experimental drugs that block the trigger of allergic reactions before symptoms show.
The first known patient cases using magnetic resonance-guided heat (laser interstitial thermal therapy) or cold (cryoablation) to treat prostate cancer recurrence after surgical removal of the prostate gland were presented by physicians at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa. Many of these patients have also failed salvage radiation treatment and are often presented with limited therapeutic options. MR-guided focal therapy offers a new treatment choice for patients because of the improved detection of early prostate cancer recurrences best seen with MR imaging.
Eli Lilly and Company and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.
Esteya, an electronic brachytherapy system, has received 510(k) clearance from the U.S. Food and Drug Administration, enabling medical centers in the United States to offer their patients with skin cancer a new treatment option.
› Verified 4 days ago
| Entity Name | Houlton Regional Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386804268 PECOS PAC ID: 0042127946 Enrollment ID: O20041123000733 |
News Archive
Scientists at St George's, University of London and the University of Manchester have received an additional Seeding Drug Discovery award of £390,000 from the Wellcome Trust to explore a new class of experimental drugs that block the trigger of allergic reactions before symptoms show.
The first known patient cases using magnetic resonance-guided heat (laser interstitial thermal therapy) or cold (cryoablation) to treat prostate cancer recurrence after surgical removal of the prostate gland were presented by physicians at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa. Many of these patients have also failed salvage radiation treatment and are often presented with limited therapeutic options. MR-guided focal therapy offers a new treatment choice for patients because of the improved detection of early prostate cancer recurrences best seen with MR imaging.
Eli Lilly and Company and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.
Esteya, an electronic brachytherapy system, has received 510(k) clearance from the U.S. Food and Drug Administration, enabling medical centers in the United States to offer their patients with skin cancer a new treatment option.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth J Boogusch, MD 17 Rockbrook Dr, Camden, ME 04843-1616 Ph: (207) 390-0647 | Elizabeth J Boogusch, MD 17 Rockbrook Dr, Camden, ME 04843-1616 Ph: (207) 390-0647 |
News Archive
Scientists at St George's, University of London and the University of Manchester have received an additional Seeding Drug Discovery award of £390,000 from the Wellcome Trust to explore a new class of experimental drugs that block the trigger of allergic reactions before symptoms show.
The first known patient cases using magnetic resonance-guided heat (laser interstitial thermal therapy) or cold (cryoablation) to treat prostate cancer recurrence after surgical removal of the prostate gland were presented by physicians at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa. Many of these patients have also failed salvage radiation treatment and are often presented with limited therapeutic options. MR-guided focal therapy offers a new treatment choice for patients because of the improved detection of early prostate cancer recurrences best seen with MR imaging.
Eli Lilly and Company and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.
Esteya, an electronic brachytherapy system, has received 510(k) clearance from the U.S. Food and Drug Administration, enabling medical centers in the United States to offer their patients with skin cancer a new treatment option.
› Verified 4 days ago